What 4 Analyst Ratings Have To Say About Tandem Diabetes Care
Portfolio Pulse from Benzinga Insights
Recent analyst ratings for Tandem Diabetes Care (NASDAQ:TNDM) show a mix of opinions, with an average 12-month price target of $32.5, reflecting a 34.02% increase from the previous target. Analysts from Citigroup and Stifel have raised their price targets, indicating a positive outlook on the company's performance despite a -10.75% decline in revenue growth and challenges in profitability and debt management. Tandem Diabetes Care, known for its insulin pumps, has a significant market presence but faces financial performance issues.
April 03, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have a mixed but generally positive outlook on TNDM, with recent upgrades and a significant increase in the 12-month price target. Despite facing a revenue decline and financial challenges, the company's market presence and product offerings keep analysts optimistic.
The positive adjustment in price targets by analysts from Citigroup and Stifel, despite Tandem Diabetes Care's recent revenue decline and financial challenges, suggests a belief in the company's potential for recovery and growth. This optimism is likely based on the company's strong market presence and the essential nature of its diabetes care products.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100